Novo Nordisk recently announced that the US Food and Drug
Administration (FDA) has approved the New Drug Application (NDA) for
Saxenda® (liraglutide 3 mg), the first once-daily human glucagon-like
peptide-1 (GLP-1) analogue for the treatment of obesity.
Saxenda® is
indicated as an adjunct to a reduced-calorie diet and increased physical
activity for chronic weight management in adults with obesity (BMI =30
kg/m2) or who are overweight (BMI =27 kg/m2) with at least one
weight-related comorbidity such as type 2 diabetes and cardiovascular
disease, said a statement. "Many people with obesity suffer from
comorbidities. Saxenda® has the potential to help some of these people
achieve and maintain a clinically significant weight loss and improve
their weight-related comorbidities," said Mads Krogsgaard Thomsen.
— Statement
— Statement
Blogger Comment
Facebook Comment